GlassScriptPhysician profile
Mohammed A Bhatti
NPI 1629159512
$818.93
in general payments reported to CMS, 2019-2025
17 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2022: $139 · 2023: $300 · 2024: $40.32 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $123.53 | 2019-2025 | |
| Ucb, INC. | $110.88 | 2022-2025 | Rystiggo, Briviact |
| Genentech USA, INC. | $72.96 | 2022-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $61.24 | 2023-2025 | Lyvispah, Crexont |
| Lilly USA, LLC | $55.83 | 2022-2023 | Emgality, Reyvow |
| Sunovion Pharmaceuticals INC. | $54.27 | 2019 | |
| Lundbeck LLC | $47.74 | 2022-2024 | Vyepti |
| Medtronic, INC. | $41.20 | 2022-2023 | Linq II |
| Biogen, INC. | $39.65 | 2023 | Tysabri, Vumerity |
| Impel Pharmaceuticals INC. | $38.78 | 2023 | Trudhesa |
| Pfizer INC. | $37.32 | 2025 | |
| Ani Pharmaceuticals, INC. | $30.85 | 2025 | Purified Cortrophin Gel |
| Alexion Pharmaceuticals, INC. | $23.73 | 2023 | Soliris |
| Horizon Therapeutics Plc | $22.45 | 2022 | |
| Cycle Pharmaceuticals INC | $21.52 | 2024 | Tascenso Odt |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $18.77 | 2022 | |
| Argenx US, INC. | $18.21 | 2023 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Bhatti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.